[Cervical cancer screening: what role for methylation tests?]

Area of Science:

• Oncology
• Virology
• Epigenetics

Background:

• Cervical cancer arises from persistent high-risk human papillomavirus (HR-HPV) infections.
• Current screening relies on cytology and HR-HPV detection, necessitating effective triage for HR-HPV positive individuals.
• Identifying women at high risk of progression is crucial to prevent invasive procedures and overtreatment.

Purpose of the Study:

• To evaluate DNA methylation analysis as a triage tool for HR-HPV positive women.
• To assess the potential of methylation markers in stratifying cervical cancer risk.
• To explore the impact of methylation testing on reducing unnecessary colposcopies and conizations.

Main Methods:

• Investigated DNA methylation analysis as an epigenetic biomarker for cervical cancer risk stratification.
• Examined methylation markers targeting viral genes (L1, L2) and host genes (FAM19A4, CADM1, MAL).
• Considered applicability to both cervical smears and self-collected vaginal samples.

Main Results:

• DNA methylation analysis is emerging as a promising triage tool for HR-HPV positive women.
• Methylation markers demonstrate potential for stratifying risk of cervical cancer progression.
• The application of these tests could reduce invasive examinations and overtreatment, preserving future fertility.

Conclusions:

• DNA methylation analysis offers a potential advancement in cervical cancer screening triage.
• Further comparative studies are needed to determine the optimal place of methylation tests in screening strategies.
• Selection of the most relevant methylation test requires ongoing investigation to refine cervical cancer management.